PATH | VRL
Menu

Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects

This article, published in Clinical and Vaccine Immunology, reports the results of a Phase 1 clinical study that evaluated the safety and immunogenicity of a Shigella vaccine candidate. The results showed that the vaccine was well tolerated and elicited immune responses in healthy adult volunteers. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Chakraborty S, Harro C, DeNearing B, et al.

Published: 2016

» Visit web page (English)

(Located at cvi.asm.org)

Citation: Chakraborty S, Harro C, DeNearing B, et al. Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects. Clinical and Vaccine Immunology. 2016;23(4):315-325. 

Resource types: Peer-reviewed journal

Diseases/vaccines: Shigellosis and enterotoxigenic Escherichia coli (ETEC)

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: North America and Europe